Empagliflozin Effect on Left Cardiac Parameters in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Autor:	Eljadid GY; Faculty of Medicine, Ain Shams University, Cairo, EGY., Rakab MS; Faculty of Medicine, Mansoura University, Mansoura, EGY., Mansour A; Faculty of Medicine, Al-Azhar University, Cairo, EGY., Almosilhy NA; Faculty of Pharmacy, Tanta University, Tanta, EGY., Abbas AW; Faculty of Medicine, Mansoura University, Mansoura, EGY., Abdrabou N; Faculty of Medicine, Alexandria University, Alexandria, EGY., Alarab AS; Faculty of Medicine, University of Aleppo, Aleppo, SYR., Mohamed YA; Faculty of Medicine, Cairo University, Cairo, EGY., Khaled A; Faculty of Medicine, University of Beni Suef, Beni Suef, EGY., Goufa E; Faculty of Medicine, University of Oran 1 - Ahmed Ben Bella, Oran, DZA., Elbataa A; Faculty of Medicine, Al-Azhar University, Cairo, EGY., Aboeldahab HA; Faculty of Pharmacy, Alexandria University, Alexandria, EGY.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Sep 11; Vol. 16 (9), pp. e69229. Date of Electronic Publication: 2024 Sep 11 (Print Publication: 2024).
DOI:	10.7759/cureus.69229
Abstrakt:	Acute coronary syndrome (ACS) poses a significant global health burden despite advancements in its management. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, primarily used in type 2 diabetes mellitus (T2DM), have gained recent consideration as potential agents for ACS management due to their cardiovascular benefits beyond glycemic control. This study aimed to assess the effects of empagliflozin on left cardiac parameters in ACS patients. PubMed, Cochrane, Scopus, and Web of Science were searched thoroughly to identify relevant randomized controlled trials (RCTs). Four RCTs involving 701 patients were included. Compared to placebo, empagliflozin significantly reduced left ventricular end-systolic volume index (mean difference (MD): -2.38, 95% CI: -3.95 to -0.80, p = 0.0032), left ventricular mass index (MD: -2.76, 95% CI: -4.95 to -0.56, p = 0.0137), and left ventricular filling pressure (MD: -0.59, 95% CI: -1.07 to -0.10, p = 0.0189). However, empagliflozin treatment did not yield a statistically significant change in left ventricular ejection fraction (MD: 1.21, 95% CI: -0.05 to 2.48, p = 0.0603) nor a significant change in left ventricular end-diastolic volume (MD: -4.49, 95% CI: -14.24 to 5.26, p = 0.37), left ventricular end-systolic volume (MD: -5.19, 95% CI: -10.77 to 0.39, p = 0.0682), and left ventricular end-diastolic volume index (MD: -2.20, 95% CI: -4.59 to 0.19, p = 0.0718). Empagliflozin provides favorable effects on left cardiac structural parameters in ACS patients. This suggests a potential role for SGLT2 inhibitors as adjunctive therapy in ACS management, warranting further investigation into their mechanisms and long-term clinical outcomes. Competing Interests: Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Eljadid et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu